Weight loss is common among patients with advanced cancer and contributes to poor treatment response, deterioration in quality of life (QOL) and decreased survival. 1 There are two types of weight loss in patients with cancer: cancer cachexia and chemotherapy-induced weight loss.
Cancer cachexia is particularly common in lung, gastric, pancreatic and prostate cancers. 2 The pathophysiology of cachexia is multifactorial and is still not well-understood. It is proposed to be the result of tumor-host interactions. 3 The cachexia guideline expert group identified cancer cachexia as a continuum of three stage of clinical relevance: pre-cachexia, cachexia and refractory cachexia. 4 Refractory cachexia represents a stage where reversal of weight loss seems no longer possible. In this stage, the burdens and risks of artificial nutritional support likely outweigh expected benefit. Early, namely the stage of pre-cachexia intervention is essential. 4 The major causes of chemotherapy-induced weight loss are adverse events such as nausea and vomiting. Chemotherapy-induced nausea and vomiting (CINV) is the most common and intolerable adverse event of cytotoxic chemotherapy. It causes reduced oral intake 5 and has negative impacts on QOL. 6, 7 To prevent chemotherapyinduced weight loss, several nutrition interventions such as dietary counseling (DC) and high-energy oral nutritional supplement (ONS) for patients with advanced cancer have been undertaken. However, these interventions have shown no improvement in nutritional parameters [8] [9] [10] [11] owing to poor compliance to the nutritional intervention and poor treatment outcomes of CINV. 8 In brief, uncontrollable CINV reduced the positive effects of nutritional interventions with DC and ONS.
Fortunately, recent advances in CINV treatment for the past 10 years, particularly the development of new-generation antiemetic drugs, has considerably improved outcomes. The efficacy of aprepitant for CINV was confirmed in clinical trials globally [12] [13] [14] including in Japan. 15 It was approved by the United States Food and Drug Administration in 2003 and by the Ministry of Health, Labor and Welfare in Japan in 2009. Major clinical practice guidelines on antiemetics classify cisplatin-based chemotherapies as highly emetogenic chemotherapies (HEC) and strongly recommend aprepitant-containing 3-drug regimens, including a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA) and dexamethasone. [16] [17] [18] [19] Since then, acute-and delayedphase CINV has been less severe, and the QOL of patients with cancer has improved. 6, 7 However, weight loss still occurs frequently despite antiemetic treatments in patients with lung cancer during cytotoxic chemotherapy. Weight loss is generally caused by reduced oral intake and is a serious problem among patients with cancer. 5 Most previous studies on nutrition interventions with DC and/or ONS [8] [9] [10] [11] have been undertaken before new guidelines on antiemetics have been established. [16] [17] [18] [19] This study aimed to investigate the effect of early nutrition intervention on body weight during the course of chemotherapy with appropriate antiemetic treatments in patients with lung cancer. We hypothesized that intensive nutrition intervention may prevent chemotherapy-induced weight loss based on the appropriate antiemetic treatments.
MATERIALS AND METHODS

Patients
This study is registered in the UMIN registry system (No. 000030785). Consecutive patients with histologically proven inoperable or recurrent non-small-cell lung cancer between August 2017 and May 2018 in Tottori University Hospital, Japan, who were scheduled for the first line cytotoxic chemotherapy were eligible for inclusion. Patients received individualized nutrition counseling by a registered dietitian and were provided with ONS for 90 days. The duration was set based on standard period of first line chemotherapy. To evaluate the nutrition intervention, we also retrospectively enrolled patients as control. The following outcome parameters were measured at baseline and 90 days after commencing chemotherapy.
The following outcome parameters were measured at baseline and 90 days after commencing chemotherapy (Fig. 1) .
Retrospective controls
To compare between patients with and without early intensive nutrition intervention, we retrospectively reviewed the clinical data and body weight of 38 consecutive patients with inoperable or recurrent nonsmall-cell lung cancer who were given cytotoxic chemotherapy in Tottori University Hospital between April 2014 and March 2016. These patients were considered as the retrospective controls. They all received three or more cycles of cytotoxic chemotherapies with new recommended antiemetic drugs.
Nutrition intervention
Patients received individualized nutrition interventions in the form of intensive nutrition counseling by a registered dietitian once a month. They were held in the interview room for 30 minutes or more. A registered dietitian calculated the total amount of calorie intake through counseling and questionnaire (described below for details) and determined those with insufficient nutrient intake. To estimate total energy needs, physical activity and disease factors were included. Basal energy expenditure (BEE) was estimated using the Harris Benedict equation. 20 To calculate total energy expenditure (TEE), we multiplied BEE by an activity factor of 1.4 by an injury factor of 1.2. 21 Based on the actual calorie intake and requirements, a registered dietitian provided individual sample meal plans, recipe suggestions, and suggestions to minimize the side effects of the tumor pathology and therapy. They were recommended to take nutritional supplements to increase calorie intake. Attending doctors, dietitians, and nurses comprised the nutrition intervention team, and they conducted a nutrition meeting once monthly to discuss the patient's nutrition status and other clinical information.
Nutritional supplement MHN-02(MEIN, Meiji Dairies Corporation, Tokyo, Japan) was used as ONS in this study. In general, MHN-02 is a whey peptide with anti-inflammatory and antioxidant components such as vitamins C and E and enriched trace elements (i.e., zinc and selenium). 22 Patients were allowed to consume as much as they wanted based on nutrition counseling, and the daily intakes were recorded in a diary.
Data collection Anthropometric measurements
Body composition was taken by the same two trained investigators throughout the study and analyzed with bioelectrical impedance analysis with an InBody720 (InBody Japan Corp. Tokyo, Japan). This system uses an electrical current at different frequencies (5, 50, 250, 500, and 1000 kHz) to directly measure the amount of extracellular and intracellular water in the body. The patient stands with the soles in contact with the foot electrodes and grabs the hand electrodes. Data output included fat mass, skeletal muscle mass of the total body, arms and legs, and basal metabolic rate and was calculated by using the manufacturer's algorithm. The muscle mass was converted into the skeletal muscle mass index (SMI) by dividing the weight by the height squared (kg/ m 2 ).
Handgrip strength
Handgrip strength was measured using a digital gripstrength meter (TKK5401; Takei Scientific Instruments Co, Ltd, Niigata City, Japan). Participants performed the tests twice in both hands in a standing position. The mean of measurements was used.
Blood examination
For biochemical testing, total protein, albumin, and hemoglobin were measured as nutrition indices. C-reactive protein and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) were measured as inflammatory markers. Standard blood laboratory parameters were analyzed using fresh samples in accordance with routine protocols at the hospital. Serum pro-inflammatory cytokines were measured using commercially available enzyme-linked immunosorbent assay k its (R&D systems, Inc. Minneapolis, MN).
Quality-of-life assessment
QOL was measured using EuroQol-5 Dimensions, 5 Levels (EQ-5D-5L). We used Japanese interim EQ-5D value set estimated with official crosswalk methodology as developed by the EuroQol Group, which is a validated measure of health-related QOL. It comprises a five-dimension health status classification system and a separate Visual Analogue Scale. 23 
Nutritional status
Patients answered a brief-type self-administered diet history questionnaire (BDHQ) to provide data for nutrition intake estimates. 24, 25 The BDHQ comprised four pages with 75 questions that assessed dietary habits during the past 1 month: 55 questions were related to food consumption and 17 were on cooking and dietary behaviors. The daily intake estimates for foods, energy, and selected nutrients were calculated using an ad hoc computer algorithm developed for the BDHQ, which was based on the Standard Tables of Food Composition in Japan. Body weight and other parameters were measured at baseline and after 90-day intervention. BDHQ, brief-type self-administered diet history questionnaire; EQ-5D-5L, EuroQol-5 Dimensions, 5Levels; ONS, oral nutritional supplement; QOL, quality of life; VAS, Visual Analogue Scale.
CINV
Nausea and vomiting that occurred within 14 days after commencing chemotherapy were defined as CINV and was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (version 4.0).
Statistical Analysis
Continuous data were expressed as mean ± standard deviation or median and interquartile range. Outcome parameters were compared between at baseline and after 90-day intervention using paired t-test. Multivariate logistic regression analysis was used to compare body weight and BMI changes between patients and retrospective controls. In addition, inverse probability of treatment weighting (IPTW)-adjusted analyses were performed to account for baseline differences. 26 The propensity to undergo nutritional intervention in the patients versus retrospective controls was estimated using a logistic regression model based on age, sex, chemotherapy (platinum-based doublet chemotherapy or not), body height, and body weight. Propensity scores were then used to derive IPTW, with the inverse of the propensity score for patients of the study group and the inverse of 1 minus the propensity score for patients of the retrospective control group. Then, the generalized estimating equations were used to compare body weight change during 90 days in the two groups.
Statistical significance was determined as P < 0.05 with a two-sided test. All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software Inc., San Diego, CA) and SPSS Statistics 25 (IBM Japan Ltd., Tokyo, Japan).
Ethics
This study was reviewed and approved by the Ethics Committee of Tottori University (#1704B001) and was performed according to the Declaration of Helsinki. 27 All patients provided written informed consent.
RESULTS
A total of 10 consecutive patients were included. They were recruited between August 2017 and May 2018 and followed up from August 2018 until trial ended. The cohort comprised 6 men and 4 women and the median age was 68.5 (range, 28-83) years. Table 1 shows the baseline characteristics of the patients. All patients received cytotoxic chemotherapy; eight patients received three cycles of chemotherapy, while two patients received only two cycles of chemotherapy because of disease progression. Eight patients received standard platinum-based doublet chemotherapies with recommended aprepitantcontaining 3-drug antiemetic regimens, and the two patients received non-platinum single-agent chemotherapies with recommended 2-drug antiemetic regimens.
All patients received 90-day nutrition intervention. Table 2 summarizes the outcome parameters of the patients. The mean body weight, BMI and QOL mildly increased; however, the increases were not statistically significant. The highest body weight gain was 6.3 kg, and the highest body weight loss was 2.0 kg because of disease progression. Handgrip strength showed significant decrease, while total SMI, arm SMI and leg SMI did not increase between baseline and after 90-day intervention.
The pro-inflammatory cytokines TNF-α, IL-6 and IL-1β play a central role in the pathogenesis of cancerrelated body weight loss and cachexia. 28, 29 Moreover, reduction in inflammation prevents body weight loss and cachexia. 30, 31 In our study, the amounts of inflammatory markers such as CRP, TNF-α, IL-6 and IL-1β were higher than normal even at baseline, and they did not de- IIIB or IV 9 (90%) Recurrence 1 (10%) Chemotherapy, n (%) Platinum-based doublet chemotherapy 8 (80%) Non-platinum chemotherapy 2 (20%) EGFR, epidermal growth factor receptor; EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion; n, number of cases (% total cases); ROS1 fusion, c-ros oncogene 1 receptor tyrosine kinase fusion. Data are presented as the mean ± SD.
crease after the 90-day intervention. The mean dietetic consumption of the participants at baseline was approximately 25% lower than the TEE, which was estimated using the Harris Benedict equation. TEE is affected by an activity factor and an injury factor. In addition, after the 90-day intervention, dietetic consumption did not show significant decrease although all patients received cytotoxic chemotherapies. Seven of the ten participants consumed nutritional supplements, and the mean intake was approximately 130 kcal/day. Eicosapentaenoic acid (EPA) intake significantly increased after the 90-day intervention. Meanwhile, there were no significant changes in statistics and dietetic consumption of total kilocalories, proteins, and fat after the 90-day intervention (Table 2) .
In general, the body weight of patients with lung cancer tend to decrease during cytotoxic chemotherapy. In the present study, there were no remarkable decreases of body weight ( Table 2) . As for a comparison between patients with and without early intensive nutrition intervention, there were no significant characteristic differences between the study cohort and the retrospective controls. Moreover, the frequency of CINV was not significantly different between the two groups (Table 3) . Meanwhile, compared with the retrospective control, the number of the patients who gain the body weight after 90 days in the study cohort was significantly larger than that in the retrospective controls with the IPTW analysis [Odds Ratio (OR) = 8.4; 95% Confidence Interval (CI): 1.6-42; P = 0.01] ( Table 4) .
DISCUSSION
Chemotherapy-induced weight loss is among the serious problems in cancer treatment. The present study demonstrated that individualized intensive nutrition intervention reduced weight loss during the course of cytotoxic chemotherapy. Furthermore, the body weight change of the study cohort was significantly different with that of the retrospective controls on IPTW analysis. The patients received adequate antiemetic drugs and high-quality nutritional information and education, thereby reducing weight loss during cytotoxic chemo- 46.0 ± 74 51.7 ± 24 Ns n-3 fatty acid (g/day)
2.0 ± 0.9 2.7 ± 1.4 Ns α-linolenic acid (g/day)
1.3 ± 0.8 1.6 ± 0.8 Ns EPA (g/day) 0.22 ± 0.13 0.42 ± 0.26 0.038 DHA (g/day) 0.38 ± 0.18 0.56 ± 0.38 Ns *After 90-day intervention of dietetic consumption includes both food intake and nutritional supplement. Data are presented as the mean ± SD. Statistical analysis was performed with paired t-test. P < 0.05 was considered statistically significant. BMI, body mass index; CHO, carbohydrates; CRP, c-reactive protein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EQ-5D-5L, EuroQol5 dimensions 5 levels; IL-1β, interleukin-1β; IL-6, interleukin-6; Kcal, kilocalories; Ns, not significant; QOL, quality of life; SMI, skeletal mass index; TNF-α, tumor necrosis factor; VAS, visual analogue scale. Alb, albumin; CINV, chemotherapy-induced nausea and vomiting; Cr, creatinine; CRP, c-reactive protein; Hb, hemoglobin; LDH, lactic acid dehydrogenase; n, number of cases (% total cases); Ns, not significant; PD, progressive disease; Plt, platelet; PR, partial response; SD, stable disease; TP, total protein; WBC, white blood cell. 30 (79%) IPTW analysis for the study patients versus retrospective controls was estimated using a logistic regression model based on age, sex, chemotherapy (platinum-based doublet chemotherapy or non-platinum chemotherapy), body height, and body weight. *chi-square test; †generalized estimating equations. CI, confidence interval; IPTW, inverse probability of treatment weight; OR, odds ratio.
therapy.
In previous studies, nutrition interventions such as DC and/or ONS yielded no improvement in body weight, [9] [10] [11] but ONS with EPA and DHA-enriched supplementation resulted in a significant improvement in patients with cancer during chemotherapy. 8, [31] [32] [33] Meanwhile, in the current study, nutrition intervention without EPA and DHA-enriched supplement caused increased body weight in the patients compared with the retrospective control. This outcome might be due to two reasons. First, the control of CINV has considerably improved in the past 10 years. The availability of aprepitant in addition to other antiemetic agents, such as 5-HT3RA and dexamethasone, has improved treatment outcomes of CINV. Currently, 3-drug regimens (aprepitant, 5-HT3RA and dexamethasone) are strongly recommended to prevent CINV during HEC. [16] [17] [18] [19] Consequently, the present study shows that appropriate nutrition intervention with antiemetic drugs prevented reduced dietary intake and body weight from CINV. Second, dietary intake of EPA and DHA among Japanese is generally higher than that in other populations. EPA and DHA-enriched supplementation 8, [31] [32] [33] causes weight gain as they can downregulate the production of proinflammatory cytokines and mediate the modulation of systemic inflammation. 34, 35 As such, EPA and DHA reduce anorexia, resting energy expenditure, muscle degradation and weight loss. [36] [37] [38] [39] The EPA and DHA intake of Japanese is approximately four-fold higher compared to that of Americans. Based on the results of the 2005 and 2006 NHNS, 40 the median EPA and DHA intake of Japanese aged 30-49 years is 0.32 g/day in men and 0.23 g/day in women, while it is 0.086 g/day in men and 0.063 g/day in women among Americans aged 31-50 years. 41 In this study, the consumption of EPA at baseline and after 90-day intervention were 0.22 ± 0.13 g/day and 0.42 ± 0.26 g/day and DHA at baseline and after 90-day intervention were 0.38 ± 0.18 g/day and 0.56 ± 0.38 g/day, respectively. The patients took adequate amounts of EPA and DHA daily. For patients who take enough fish oil like the Japanese, nutrition intervention may have strong effect on preventing weight loss even without EPA and DHA supplementation.
Weight loss in cancer patients administered chemotherapy consists of chemotherapy-induced weight loss and cancer cachexia. These two are interconnected and inseparable. The efficacy of nutritional intervention on cancer cachexia was not assessed in this study. In a short period of 90-day intervention, the patients had increased BMI, while they did not gain SMI, and had reduced grip strength. Patients with muscle depletion and low muscle attenuation have worse prognoses independent of other factors. 42 The importance of rehabilitation and exercise for cancer patients has been recently recognized. Vigorous exercise and physical activity were associated with lower risk of colorectal cancer-related overall mortality, 43 prostate cancer progression, 44 and reduced symptoms of lung cancer. 45 Future research should pay attention to not only nutrition intervention but also physical intervention, such as rehabilitation or exercise.
In conclusion, early intensive nutritional intervention during chemotherapy resulted in maintenance of body weight compared with patients who received standard care. With the development of antiemetic drugs to prevent CINV, nutrition interventions such as DC and ONS might be beneficial not only for body weight but also clinically relevant outcomes such as QOL, treatment response and survival.
LIMITATIONS
This study has some limitations. First, although improvements in clinically relevant outcomes such as treatment response and survival are primary targets for nutrition intervention, the effects of these outcomes had not been assessed in this study. Second, the number of patients was too small, and this study was single arm. Larger randomized trials are required in the future.
